Efficacy of Human Monoclonal Antibodies Against H5N1 Influenza

Monoclonal antibodies generated from B cells of patients who had survived H5N1 influenza were efficacious in preventing and treating H5N1 infection in a mouse model.

Although currently circulating H5N1 viruses are not efficiently transmitted from person to person, H5N1 influenza remains a major global threat. New treatment strategies are urgently needed. Now, researchers (one of whom is named on a patent relating to the generation and use of human monoclonal antibodies) have generated anti-H5N1 monoclonal antibodies (mAbs) from B-cells of four Vietnamese patients who survived H5N1 infections. They selected four mAbs that demonstrated broad in vitro neutralizing activity against H5N1 and tested their prophylactic and therapeutic efficacy in BALB/c mice. These animals are highly susceptible to infection with the H5N1 viruses isolated in Asia in 1997 and since 2003.

Two mAbs were tested for pre-exposure pro…

Reviewing Author

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Efficacy of Human Monoclonal Antibodies Against H5N1 Influenza

Topics

Reviewing Author